{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.0","upperLimit":"30.8","value":"21.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"CRR is the percentage of patients with at least one visit response of CR based on CT scans evaluated by IRC per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group D"}],"paramType":"NUMBER","populationDescription":"Evaluable for CT-based Response Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part B: Complete Response Rate (CRR) Assessed by IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}